The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

BioSyent

  • RX
  • TSX Venture
  • Consumer Products
  • Latest 7.42
  • Currency C$
  • Change 0.76
  • Percent Change 11.411 %
  • Volume 63,814
  • Wed Jul 23, 2014 03:59 PM EDT TSX Venture data delayed 15 minutes.
  • Open 6.92
  • Previous Close 6.66
  • High 7.48
  • Low 6.91
  • Bidx600 7.31
  • Askx700 7.42
  • 52-week High06/09 8.19
  • 52-week Low07/31 1.45
  • Beta 0.261
  • Market Cap 98.47M
  • EPS 0.12
  • P/E 61.833
  • Forward P/E
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $5,039,062
  • Earnings $1,541,317
  • Return on Equity 77.03%

Cash Flow

  • Cash Flow $1,372,350
  • Cash $2,316,054
  • Current Ratio 4.08

12 months ended Dec 31, 2012.

Trailing 12 month results shown above.
All data is in Canadian dollars.

Balance Sheet

  • Assets $3,652,770
  • Liabilities $813,361
  • Liabilities-to-Equity Ratio 0.29

Price Ratios

  • Price to Sales 18.98
  • Price to Book 34.67
  • Price to Cash Flow 69.35

Event Calendar

Event Last   Next  
Earnings May 28 n/a Aug 28 n/a
Surprises n/a n/a n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Jul 23, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

BIOSYENT INC. sources, acquires or in-licences pharmaceutical products and markets these products in Canada. BioSyent Pharma Inc. sells pharmaceutical products, Hedley Tech markets bio and health friendly non-chemical insecticides.

Related Securities
Symbol Type Latest % Chg

Officers

  • Rene C. Goehrum President & C.E.O.
  • Alfred D'Souza V.P. & C.F.O.
  • Company Type: PUBLIC
  • Company Status: Active
  • Full-time Employees: n/a
  • Incorporation: Canada,
    Apr 28, 1947
  • Top 1000 Ranking: Profit: 0
    Revenue: 0
    Assets: 0

Head Office

170 Attwell Drive
Etobicoke, ON
M9W 5Z5

Phone: (905)-206-0013
Fax: (905)-2061413

rgoehrum@biosyent.com
www.biosyent.com

Ideas & Discussion

Live Discussion of RX on StockTwits